Trial Profile
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Studyto Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illnessin the Elderly
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2021
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary)
- Indications Respiratory tract infections
- Focus Registrational; Therapeutic Use
- Acronyms PROTECTOR; PROTECTOR-1
- Sponsors resTORbio
- 28 May 2020 Pooled analysis (ACTRN12617000468325 & ACTRN12619000628145) published in the resTORbio Media Release.
- 22 Apr 2020 Status changed from active, no longer recruiting to completed.
- 15 Nov 2019 According to a resTORbio media release, the company will host a conference call at 8:00 a.m. EST today to review these pivotal results and provide an update on additional clinical development plans for RTB101.